$13.27
At close: May 20 EDT
$13.27
0.000.00%
Pre-Market: 4:00 PM EDT
Comments
Loading...
HUTCHMED (China) Analyst Ratings and Price Targets | NASDAQ:HCM | Benzinga
HUTCHMED (China) Ltd has a consensus price target of $30.37 based on the ratings of 3 analysts. The high is $50 issued by Cantor Fitzgerald on September 5, 2023. The low is $19 issued by Goldman Sachs on August 1, 2024. The 3 most-recent analyst ratings were released by Goldman Sachs, Deutsche Bank, and Goldman Sachs on August 1, 2024, November 24, 2023, and November 10, 2023, respectively. With an average price target of $19.37 between Goldman Sachs, Deutsche Bank, and Goldman Sachs, there's an implied 45.94% upside for HUTCHMED (China) Ltd from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Goldman Sachs
Deutsche Bank
Cantor Fitzgerald
1calculated from analyst ratings
Analyst Ratings for HUTCHMED (China)
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 08/01/2024 | Buy Now | 43.18% | Goldman Sachs | Paul Choi58% | $17 → $19 | Maintains | Neutral | Get Alert |
| 11/24/2023 | Buy Now | 66.54% | Deutsche Bank | Cyrus Ng9% | $20 → $22.1 | Upgrade | Hold → Buy | Get Alert |
| 11/10/2023 | Buy Now | 28.11% | Goldman Sachs | Paul Choi58% | $15 → $17 | Maintains | Neutral | Get Alert |
| 09/05/2023 | Buy Now | 276.79% | Cantor Fitzgerald | Louise Chen52% | → $50 | Reiterates | Overweight → Overweight | Get Alert |
| 07/24/2023 | Buy Now | 276.79% | Cantor Fitzgerald | Louise Chen52% | → $50 | Reiterates | Overweight → Overweight | Get Alert |
| 08/09/2022 | Buy Now | 20.57% | Goldman Sachs | Paul Choi58% | $14 → $16 | Maintains | Neutral | Get Alert |
| 08/02/2022 | Buy Now | 5.5% | Goldman Sachs | Paul Choi58% | $16 → $14 | Maintains | Neutral | Get Alert |
FAQ
What is the target price for HUTCHMED (China) (HCM) stock?
The latest price target for HUTCHMED (China) (NASDAQ:HCM) was reported by Goldman Sachs on August 1, 2024. The analyst firm set a price target for $19.00 expecting HCM to rise to within 12 months (a possible 43.18% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for HUTCHMED (China) (HCM)?
The latest analyst rating for HUTCHMED (China) (NASDAQ:HCM) was provided by Goldman Sachs, and HUTCHMED (China) maintained their neutral rating.
When was the last upgrade for HUTCHMED (China) (HCM)?
The last upgrade for HUTCHMED (China) Ltd happened on November 24, 2023 when Deutsche Bank raised their price target to $22.1. Deutsche Bank previously had a hold for HUTCHMED (China) Ltd.
When was the last downgrade for HUTCHMED (China) (HCM)?
There is no last downgrade for HUTCHMED (China).
When is the next analyst rating going to be posted or updated for HUTCHMED (China) (HCM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of HUTCHMED (China), and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for HUTCHMED (China) was filed on August 1, 2024 so you should expect the next rating to be made available sometime around August 1, 2025.
Is the Analyst Rating HUTCHMED (China) (HCM) correct?
While ratings are subjective and will change, the latest HUTCHMED (China) (HCM) rating was a maintained with a price target of $17.00 to $19.00. The current price HUTCHMED (China) (HCM) is trading at is $13.27, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
